Archive | Funding Opportunities RSS for this section

Travel awards for patient group representatives, undergrads and grad students to attend the CADTH Symposium in Toronto. Apply by Dec 10.

Application information available at https://symposium.cadth.ca/travel-awards-program/

Since 2007, CADTH has provided financial support toward conference-related costs for more than 395 students and patient group representatives as part of our commitment to making this important event accessible to all health care stakeholders.

This year, eligible students and patient group representatives can receive up to $2,000 to offset registration, travel, food, accommodation, and other conference-related expenses.

For Students

The 2020 CADTH Symposium offers an excellent opportunity to share your research, learn about the latest advancements in health technology assessment, and interact with peers from across the country (as well as leading Canadian and international experts). If you’re a full-time undergraduate or graduate student attending a degree-granting institution in Canada and taking courses in a field relevant to CADTH’s work, we invite you to apply for a travel award.

For Patient Group Representatives

It’s important that your voice is heard. If you work for a not-for-profit, patient-related organization, or a citizen’s organization interested in health policy, we invite you to apply for a travel award.

How to Apply

Step 1: Review the 2020 CADTH Symposium Travel Award Program Criteria.

Step 2: Complete and submit the 2020 Travel Awards Application form to CADTH by December 10, 2019.

Travel award decisions will be made by the end of January 2020, and awards will be issued to successful applicants by the end of March 2020.

Reminder: The Abstract Submission Deadline for the 2020 CADTH Symposium is October 25, 2019. Priority will be given to travel award applicants who have submitted an abstract for the 2020 CADTH Symposium.

If you have questions about the 2020 CADTH Symposium, or the Travel Award Program, please contact us at symposium@cadth.ca. We’re looking forward to seeing you in Toronto in 2020.

Have an idea for a breakthrough that could revolutionize pediatric oncology? The JLABS @ Washington, DC Children’s QuickFire Challenge invites innovators to submit game changing ideas, technologies, and solutions that have the potential to impact pediatric oncology, pediatric surgery and influenza.

In honor of the new JLABS @ Washington, DC – a 32,000 square foot facility located on the new Children’s National Research and Innovation Campus from Johnson & Johnson Innovation, LLC in partnership with Children’s National Health System (“Children’s National”) – Johnson & Johnson Innovation – JLABS announces the JLABS @ Washington, DC Children’s QuickFire Challenge.

Visionaries within the fields of pediatric oncology, pediatric surgery and influenza are invited to submit innovative ideas for a total of up to $150,000 in total grant funding; one year of residency at JLABS @ Washington, DC with the use of a bench, workstation, and access to the JLABS @ Washington, DC community; and mentorship from experts at the Johnson & Johnson Family of Companies.

Johnson & Johnson Innovation is proud to be among those answering the call to prioritize pediatric care, a message widely celebrated at the 2018 State of the Union address alongside the promise of an additional $500 million in government funding for pediatric oncology research over the next 10 years.

In addition to welcoming the awardees in this QuickFire Challenge upon opening in 2020, JLABS @ Washington, DC offers residency to pharmaceutical, medical device, consumer and health technology companies that are aiming to advance the development of new drugs, medical devices, precision diagnostics and health technologies.

We encourage applications from innovators working in all aspects of pediatric oncology, pediatric surgical care, and influenza. Specific areas of focus include:

Pediatric Oncology
  • Innovations in pediatric oncology port technologies
  • Drugs that target pediatric-specific driver genes
  • Bedside, rapid tumor genetic testing
Pediatric Surgical Care
  • Pediatric-specific implants for trauma & fracture care including growth-enabling spine & trauma orthopedic implants
  • Innovative treatment options for adolescent idiopathic scoliosis
  • Surgical robotics to treat pediatric patients
Influenza
  • Pediatric-focused innovations in influenza
  • Novel solutions for influenza vaccine delivery
  • Influenza pre-exposure including antivirals prophylaxis formulation

Applications will be accepted across:

  • Pharmaceuticals
  • Medical devices
  • Consumer products
  • Global public health
  • Health technologies
  • Cross-sector initiatives (an integration of one or more areas of focus mentioned above)

Submissions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in the current market
  • Quality & feasibility of the technology
  • Team credibility & capabilities
  • Plans for utilizing JLABS @ Washington, DC

Idea submission outlines interest in the innovation ecosystem in Washington, D.C.

Rewards and benefits
  • Up to $150,000 in total grant funding*
  • One year of residency at JLABS @ Washington, DC with the use of a bench, workstation, and access to the JLABS @ Washington, DC community
  • Mentoring by the Johnson & Johnson Family of Companies *Total grants available for awardee(s).

Canadian Cancer Society funding opportunities.

Innovation Grants

http://www.cancer.ca/en/research/grants-and-awards/current-funding-opportunities/innovation-grants/

Innovation Grants support the highest quality creative problem solving in cancer research. The goal of the Innovation program is to support the development and testing of transformative, paradigm-shifting concepts and approaches to address problems in cancer research, enhance our understanding of cancer, and generate novel approaches to confront the challenges we face in defeating cancer.

Budgets awarded may be up to $100,000 per year and a maximum of $200,000 per grant.

It is anticipated that approximately 30 grants will be awarded in this competition.

Please note the following:

  • Full application deadline: October 15, 2019
  • This competition consists of a full application only, abstract registration is not required
  • There must be no (0%) overlap with any pending or held grant applications (i.e. 100% unique aims are required – conceptual overlap is acceptable but must be described by the applicant)

Special funding calls within the Innovation Grant competition envelope:

  • Applications relevant to breast cancer research are encouraged
  • Applications relevant to skin cancer are encouraged
  • As a result of a generous donation, funding for one application with a focus on early detection, diagnosis, and/or treatment of malignant mixed Müllerian tumours (MMMT) is available
  • Additional funds may be available from the Lotte and John Hecht Memorial Foundation to support innovative projects focused on the application of complementary and alternative approaches in cancer treatment and control

Innovation to Impact Grants

http://www.cancer.ca/en/research/grants-and-awards/current-funding-opportunities/innovation-to-impact-grants/

Please note that only investigators with a funded Innovation or CBCF research grant with a project end date between January 1, 2017 and April 30, 2020 are eligible for this program. These grants are intended to support the next phase following a productive CCS Innovation Grant or CBCF research grant, with the goal of working towards or achieving a significant impact on cancer.

Full application deadline: October 15, 2019

Canadian Cancer Society travel awards for PhD, MD, MD/PhD students, and post-doctoral/medical/clinical fellows

http://www.cancer.ca/en/research/grants-and-awards/current-funding-opportunities/travel-awards/

These awards are intended to defray the travel costs associated with making a scientific presentation as a first author or presenter at a conference, symposium or other appropriate professional meeting. PhD, MD, or MD/PhD students, and post-doctoral/medical/clinical fellows are eligible to apply.

There are three competitions in 2019. It is anticipated that approximately 10 Travel Awards will be awarded in each competition (approximately 30 awards per year).

Please note the following:

  • Applications will only be accepted for conference dates within 6 months following the funding start date.
  • Eligible expenses include: 1) Conference registration fees; 2) Accommodations; and 3) Transportation, and will not exceed $2,000.
  • Individuals may receive this award only once per stage of training (PhD, MD, Post-doctoral fellow). Unsuccessful applicants may reapply in subsequent competitions.
  • Full application deadline: September 15, 2019

Travel Awards for PhD and MD/PhD students and post-doctoral/medical/clinical fellows [next due date 15-May-2019]

www.cancer.ca/en/research/grants-and-awards/current-funding-opportunities/travel-awards/

The Travel Awards program to support PhD or MD/PhD students and post-doctoral/medical/clinical fellows to present data at a conference, symposium or other appropriate professional meeting will be launched April 1st for the May 15, 2019 deadline.

There are normally three competitions each year:

1st Competition 2nd Competition 3rd Competition

Full application
deadline

January 15

May 15

September 15

Results
announcement

March

July

November
Funding start
date
April 1
August 1December 1

For those seeking support to attend the Canadian Cancer Research Conference in Ottawa in November this year, please apply for funding during this round (see eligible conference dates for this program).

Cannabis Research in Priority Areas Team Grants

The Canadian Institutes of Health Research Institute of Cancer Research (ICR) and Institute of Neurosciences, Mental Health and Addiction (INMHA), in partnership with the Canadian Cancer Society, will support Research investigating the benefits and/or harms related to therapeutic use of cannabis in people living with cancer.

See CIHR grant page HERE

The Cannabis Research in Priority Areas Team Grants is expected to:

  • •Generate new scientific knowledge that will advance our understanding of the potential benefits and/or harms of cannabis and/or cannabis use, and impact policies and programs in this area
  • Encourage interdisciplinary collaborations, including from across health research and from domains outside of health research, and the sharing of data and resources
  • Enhancing capacity development and training in cannabis research
  • Connect to existing knowledge translation efforts across Canada, for example through MHCC or the Canadian Centre on Substance Use and Addiction (CCSA)

The maximum amount per grant is $300,000 per year for up to 5 years for a total of $1.5 million, per grant. $1.5 million is available to fund an application relevant to the Cancer Pool (sponsored by the Canadian Cancer Society, ICR, and INMHA).

LOI due date: May 15, 2019
LOI notice of decision: July 15, 2019
Full application deadline: October 8, 2019
Funding start date: January 1, 2020

All applications must be submitted through CIHR’s ResearchNet. For more information view the funding opportunity details on the CIHR website.

CIHR will be hosting webinar(s) to review with participants the requirements of this funding opportunity and to answer questions. To find out more information and to register, visit the Webinars page.

CCS/CIHR Cancer Survivorship Team Grants

www.cancer.ca/en/research/grants-and-awards/current-funding-opportunities/survivorship-team-grants/

The goal of the CCS/CIHR Cancer Survivorship Team Grant program is to improve the health outcomes for cancer survivors of all ages (pediatric, adolescent, young adult and adult) from the time of their cancer diagnosis until the time of their death or entry into palliative care. This program is not intended to focus on improving end-of-life care.

The intent of this funding opportunity is to support new intervention research designed to mitigate the challenges experienced along the survivorship journey, as well as the evaluation and validation of existing interventions to assess their potential for implementation as best practices.

The program goal will be achieved through the support of a network of multidisciplinary teams, each led by a nominated Principal Investigator and at least 2 co-Principal and/or co- Investigators, one of whom must be within their first five years as an independent researcher, drawn from at least 3 different regions of Canada (Atlantic Provinces, Central Canada, Prairie Provinces, West Coast, Northern Territories). Survivors and caregivers are expected to be engaged as full and active members of research teams.

Teams may request up to $500,000 per year for a maximum of $2,500,000 over a five-year period. Grants will be non-renewable. As the total budget for this competition is $10 million, it is anticipated that at least 4 teams will be funded in this competition. The engagement of additional partners may increase this number.

Registration due date: May 29, 2019
Relevance review results: mid-June, 2019
Full application deadline: September 10, 2019
Results announcement : November 2019
Anticipated start date: December 1, 2019

All applications must be submitted through the online application system (EGrAMS) by 5p.m. EST on the deadline date. Submissions will not be accepted beyond these times.

A Webinar is planned to explain the application process and overall objectives of the call. Applicants can register by sending an email at research@cancer.ca. Details for the April 8th, 2019 (@1pm EST) webinar will be provided in advance to interested applicants.

BioCanRx Call for Letter of Intent – Bench to Bedside Translation of Innovative Cancer Biotherapeutics

Bench to Bedside Translation of Innovative Cancer Biotherapeutics

BioCanRx, Canada’s Immunotherapy Network, is pleased to announce its 2019 Call for Letters of Intent. Selected Letters of Intent will be featured in the Scientific Program of our Cycle II application going forward for review in July 2019 to the federal government’s Networks of Centres of Excellence (NCE) Program.

Building on previous BioCanRx investments in Cycle I, the overarching goal of the Cycle II Research Program will focus on extending immunotherapy successes in the clinic beyond initial responders. To address this challenge, while making use of technologies in the BioCanRx pipeline or by soliciting new complimentary technology, BioCanRx will invest in projects aimed at understanding patient and/or tumour type limitation(s) and proposing improved novel therapies, trials, or combination approaches to overcome the identified limitation(s)

Applications must be received by Wednesday, May 1, 2019.

Full details at https://biocanrx.com/research/research-program-renewal

THE CANCER RESEARCH SOCIETY IS PLEASED TO ANNOUNCE A NEW FUNDING PROGRAM: Translational Research Partnership Program

*** Pour le français, voir plus bas ***

THE CANCER RESEARCH SOCIETY IS PLEASED TO ANNOUNCE A NEW FUNDING PROGRAM

Translational Research Partnership Program

In addition to its regular funding programs, the Cancer Research Society is pleased to support high-impact translational projects throughout Canada. Our aim is to work in collaboration with partners to co-fund bold research projects in order to accelerate the development of new and innovative treatments or medical devices for the benefit of patients.

For more information on this new program, we invite you to visit our website: https://www.societederecherchesurlecancer.ca/en/researchers/translational-research-partnership

Programme de partenariat de recherche translationnelle

Programme de partenariat de recherche translationnelle

En plus de ses programmes de financement réguliers, la Société de recherche sur le cancer a plaisir d’appuyer des projets de recherche translationnelle à haut impact au Canada. L’objectif est de travailler en collaboration avec des partenaires pour cofinancer des projets de recherche audacieux afin d’accélérer le développement de nouvelles approches thérapeutiques ou de technologies médicales innovantes au bénéfice des patients.

Pour plus d’information sur ce nouveau programme, nous vous invitons à consulter notre site web. https://www.societederecherchesurlecancer.ca/fr/chercheurs/partenariat-de-recherche-translationnelle

Scholarships for the Next Generation of Scientists Competition [$50,000 PDF + $120,000 operating grant]

Please forward this message to all postdoctoral fellows interested in pursuing a career in cancer research in Canada.

The Cancer Research Society is pleased to announce the launch of its 2019 Scholarships for the Next Generation of Scientists competition, an initiative aiming at supporting future generations of Canadian researchers. The Scholarship is broken down into two parts, and extends over a period of 3 years, with no possibility for renewal.

Deadlines for submitting an application: April 26, 2019, 11:59 pm (EST).

Part 1: Postdoctoral Salary Award –  1 year * –  $50,000 One year postdoctoral salary award for a candidate finishing his/her fellowship. The candidate must have completed at least two years of postdoctoral training at the time he/she accepts the salary award.
* Possibility of extending Part 1 of this award for a maximum period of 6 months.

Part 2: Operating Grant  –   2 years – $120,000 ($60,000/year) Operating grant award once the candidate has obtained a faculty position at a recognized Canadian institution.

You have two options for submitting your application. 

  • Sending your application and accompanying documents using the button provided on our website. The deadline for submitting your electronic files is April 26 2019, 11:59 pm (EST).
  • Saving on two (2) CDs or two (2) USB keys and sending it by mail or courier, as per the instructions on our website. The deadline for mailing your application is April 26, 2019. Applications must be postmarked on or before this date.

For additional information on the competition, please visit our website

For all questions, please contact Lucille Beaudet or Irina Navarrete at grants@src-crs.ca or, toll free, 1 888-766-2262.

Thank you!

Lucille Beaudet

Director, Scientific Affairs